Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Conditions: Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathies; Systemic Sclerosis; IgG4 Related Disease; Primary Sj ögren Syndrome Interventions: Biological: T cell injection targeting CD19 chimeric antigen receptor Sponsors: PersonGen BioTherapeutics (Suzhou) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials